Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic VII: FLOX and Cetuximab in mCRC
NCT00145314Phase 3Completed
- Sponsor
- Nordic Colorectal Cancer Biomodulation Group
- Start
- May 2005
- Primary completion
- May 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Nordic Colorectal Cancer Biomodulation Group. Primary endpoint: Time to Disease Progression. Started May 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00145314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145314.